Semantic Scholar uses AI to extract papers important to this topic.
BACKGROUND An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression‐free survival, as… Expand BACKGROUND Nivolumab combined with ipilimumab resulted in longer progression‐free survival and a higher objective response rate… Expand BACKGROUND
The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously… Expand BACKGROUND
Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more… Expand BACKGROUND
An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3… Expand PURPOSE
A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free… Expand PURPOSE Three-year disease-free survival (DFS) was significantly improved in patients who had undergone resection with curative… Expand PURPOSE
As treatment options expand for metastatic colorectal cancer (mCRC), a blood marker with a prognostic and predictive role… Expand BACKGROUND
Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care… Expand Abstract Objective: To assess the influence of a specific dietary pattern on overall survival. Design: Cohort study. Setting… Expand